Payment overview · 2025
General Payments
$375.30
19 reported records · 10 companies
Healthcare provider profile · identity verified
Hernani A Valerio, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWPORT NEWS, VA · NPI 1093932444
Verified facts
What the public records show
CMS Open Payments records show Hernani A Valerio, MD received $375.30 in general payments during 2025 across 19 reported records.
Amgen Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.13 | 21.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.39 | 15.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.12 | 11.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.03 | 10.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.79 | 9.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.58 | 9.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.83 | 6.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.94 | 6.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.98 | 5.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.51 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $375.30 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.39 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.40 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $34.79 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
161 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 141 |
| Lisinopril | Lisinopril | 380 | 112 |
| Metformin Hcl | Metformin Hcl | 354 | 98 |
| Gabapentin | Gabapentin | 319 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 84 |
| Losartan Potassium | Losartan Potassium | 244 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 55 |
| Omeprazole | Omeprazole | 209 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 197 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 67 |
| Simvastatin | Simvastatin | 179 | 45 |
| Montelukast Sodium | Montelukast Sodium | 178 | 44 |
| Alendronate Sodium | Alendronate Sodium | 165 | 56 |
| Trulicity | Dulaglutide | 161 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 67 |
| Allopurinol | Allopurinol | 157 | 43 |
| Meloxicam | Meloxicam | 156 | 55 |
| Tramadol Hcl | Tramadol Hcl | 118 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 108 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 53 |
| Sertraline Hcl | Sertraline Hcl | 100 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 28 |
| Metformin Hcl Er | Metformin Hcl | 95 | 33 |
| Eliquis | Apixaban | 94 | 19 |
| Glipizide | Glipizide | 94 | 27 |
| Furosemide | Furosemide | 90 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 26 |
| Chlorthalidone | Chlorthalidone | 85 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 13 |
| Alprazolam | Alprazolam | 78 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 24 |
| Carvedilol | Carvedilol | 76 | 24 |
| Potassium Chloride | Potassium Chloride | 76 | 28 |
| Famotidine | Famotidine | 68 | 20 |
| Glimepiride | Glimepiride | 68 | 24 |
| Ezetimibe | Ezetimibe | 66 | 24 |
| Januvia | Sitagliptin Phosphate | 66 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 21 |
| Jardiance | Empagliflozin | 64 | 20 |
| Atenolol | Atenolol | 60 | 13 |
| Finasteride | Finasteride | 60 | 19 |
| Trazodone Hcl | Trazodone Hcl | 59 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 12 |
| Enalapril Maleate | Enalapril Maleate | 55 | 13 |
| Mirtazapine | Mirtazapine | 55 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 49 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 11 |
| Pregabalin | Pregabalin | 48 | 11 |
| Baclofen | Baclofen | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 11 |
| Lidocaine | Lidocaine | 43 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | 16 |
| Prednisone | Prednisone | 42 | 33 |
| Spironolactone | Spironolactone | 42 | 13 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 18 |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Hydrocortisone | Hydrocortisone | 36 | 13 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 11 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 11 |
| Azithromycin | Azithromycin | 27 | 25 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Acarbose | Acarbose | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 13 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | 11 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $375.30 · 19 records | Amgen Inc. | ACCRUFER, CAPLYTA, EVENITY, FREESTYLE LIBRE 3, KISUNLA, MOUNJARO, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, TRELEGY ELLIPTA, Tymlos, UBRELVY, Veozah, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error